fingolimod hydrochloride has been researched along with Abnormalities, Drug-Induced in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Geissbühler, Y; Moore, A; Rezaallah, B | 1 |
| Callegari, I; Derfuss, T; Galli, E | 1 |
| Alwan, S; Dahlgren, L; Lu, E; Sadovnick, AD; Synnes, A; Tremlett, H; Wang, BW | 1 |
| Langer-Gould, AM | 1 |
| Cohen, JA; Collins, W; Francis, G; Heining, P; Kappos, L; Karlsson, G; Koren, G; Zhang, X | 1 |
| Aguilera, C; Tintoré, M; Tur, C | 1 |
2 review(s) available for fingolimod hydrochloride and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Update on treatment in multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Algorithms; Antibodies, Monoclonal, Humanized; Cladribine; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Indans; Interferon-beta; Male; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Oxadiazoles; Pregnancy; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Toluidines | 2021 |
A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Multiple Sclerosis; Nitriles; Pregnancy; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Propylene Glycols; Sphingosine; Toluidines | 2014 |
4 other study(ies) available for fingolimod hydrochloride and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
An alternative to product-specific pregnancy registries? PRIM; PRegnancy outcomes Intensive Monitoring.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Drug Industry; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Maternal-Fetal Exchange; Middle Aged; Multiple Sclerosis; Pharmacovigilance; Pregnancy; Pregnancy Outcome; Registries; Young Adult | 2020 |
The pill times 2: what every woman with multiple sclerosis should know.
Topics: Abnormalities, Drug-Induced; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Propylene Glycols; Sphingosine | 2014 |
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Propylene Glycols; Sphingosine | 2014 |
[Disease modifying drugs in multiple sclerosis and pregnancy].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Infant, Newborn; Interferon-beta; Multiple Sclerosis; Natalizumab; Peptides; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Propylene Glycols; Sphingosine; Stillbirth | 2012 |